Asthma Clinical Trial
Official title:
How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction in Asthma
Airway hyperresponsiveness is a characteristic feature of the asthma. It is known that there
is an association between airway hyperresponsiveness and eosinophilic airway inflammation.
However, even though inflammation can be reduced with appropriate asthma therapy, it is
typical that airway hyperresponsiveness improves only modestly with treatment. The
determinants of airway hyperresponsiveness are unclear.
It is also not clear as to the site of airway narrowing in asthma. It is hypothesized that
airways beyond the 4th order have the greatest resistance.
We hope to determine the relationships between the airway inflammation, remodeling of the
airway and airway hyperresponsiveness. Through local instillation of methacholine at
bronchoscopy we will be able to study proximal and distal airways and the extent to which
they constrict in vivo
Airway hyperresponsiveness (AHR) is a characteristic feature of the asthmatic condition in
humans. There is an association between AHR and eosinophilic airway inflammation. However,
even though eosinophilic inflammation can be abolished with appropriate therapy, it is
typical that AHR improves only modestly with treatment. The determinants of AHR are poorly
understood. Recent data implicate mediators such as the cytokine Interleukin-13 (IL-13),
structural changes to the airway wall (remodeling), increased contractility of airway smooth
muscle cells (ASMC) and loss of mechanical connections or tethering, as potential factors
contributing to AHR.
There is also uncertainty around the site of airway narrowing in asthma. In normal airways,
bronchii around the 4th order have the greatest contribution to total resistance. It is
hypothesized that the site of greatest resistance is moved distally in asthma and might even
involve quite small airways close to the level of terminal bronchioles. Non-invasive methods
to assess airway caliber in vivo are still unproven. One untested concern is that the
airways of subjects with severe AHR have the potential to close completely putting them at
risk of severe and even fatal airflow obstruction.
We propose to study AHR in humans with asthma: we will determine the relationships between
AHR and (i) eosinophilic inflammation in the airway (sputum cellularity) via sputum
induction, (ii) soluble mediators of inflammation (IL-13, IL-4, IL-5), (iii) remodeling of
the airway wall (sub-epithelial fibrosis, ASMC accumulation)via biopsy. In addition we will
compare measurements of AHR assessed by inhalation challenge with the results of direct,
local installation of methacholine. At bronchoscopy, methacholine is delivered to the airway
and bronchoconstriction is assessed directly. This method will allow study of proximal and
distal airways, identification of heterogeneity of responses among airways and the extent to
which human airways can constrict in vivo.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|